Missouri's Mosaic Life Care stops covering $4.2M gene therapies for rare diseases, affecting families like Reed's.

Gene therapies, costing up to $4.2 million, are increasingly used for rare diseases, but many employers are cutting coverage. Mosaic Life Care in Missouri recently stopped paying for such treatments, impacting families like Amanda Reed's, whose twin boys need Zolgensma for spinal muscular atrophy. With rising therapy costs expected to reach $40 billion over the next decade, many employers are excluding these drugs, creating significant accessibility and affordability challenges for workers.

September 10, 2024
37 Articles